title: Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.
abstract: Although phase I to III trials represent the standard for introducing new drugs to clinical therapy, there has been increasing demand for translational research in oncology over the past decade. Thus, for most novel therapies such as 'targeted agents', a critical aspect for drug development in oncology has been to select the right patients for therapy. Translational research plays a pivotal role, not only in phase II trials but also in phase I and III and even in phase IV trials. The importance of distinguishing between our translational 'aims' in phase II and phase III trials is emphasized. Although translational research in phase III trials aims to identify optimal markers for clinical use, phase II studies may represent an optimal setting to explore tumour biology and the mechanisms of drug resistance in depth.
authors.affiliation: Section of Oncology, Institute of Medicine, University of Bergen, Department of Oncology, Bergen, Norway. per.lonning@helse-bergen.no
authors.forename: Per Eystein
authors.initials: PE
authors.lastname: Lønning
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans
chemical_list: D014408:Biomarkers, Tumor